Covid Vaccine Mrna. The mRNa-1273 vaccine proved to be more effective than the BNT162b2 vaccine for preventing severe Covid-19 in a real-world use comparison trial involving US. The WHO Strategic Advisory Group of Experts SAGE has issued interim recommendations for the use of the Moderna COVID-19 mRNA-1273 vaccine against COVID-19.
You may access the full guidance document here. International and local data suggest that pericarditis following mRNA COVID-19 vaccines is more common in the 25-49 year old age group for both males and females. Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing.
Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing.
Reported rates of pericarditis occurring following administration of an mRNA COVID-19 vaccine vary. Updated 25 June 2021 pursuant to updated interim recommendations. Preapproval trials showed that messenger RNA mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 had a good safety profile yet these trials were subject to size and patient-mix limitations. The mRNa-1273 vaccine proved to be more effective than the BNT162b2 vaccine for preventing severe Covid-19 in a real-world use comparison trial involving US.